Clinical Trial Update: Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 trial updates the efficacy and safety of NYX-2925 for diabetic peripheral neuropathy, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathy

Drugs mentioned

• NYX-2925

Snippet

Sponsor: Aptinyx | Conditions: Diabetic Peripheral Neuropathy | Phase 2 | Status: COMPLETED | Results posted: 2020-06-09